Walter Allison, Etienne-Selloum Nelly, Brasse David, Schleiffer René, Bekaert Virgile, Vanhoutte Paul M, Beretz Alain, Schini-Kerth Valérie B
Unité Mixte de Recherche 7175 Centre National de la Recherche Scientifique, Département de Pharmacologie et Physicochimie, Faculté de Pharmacie, Université Louis Pasteur, Illkirch, France.
J Pharmacol Exp Ther. 2009 May;329(2):699-707. doi: 10.1124/jpet.108.148080. Epub 2009 Feb 4.
Studies in both animals and humans indicate that angiogenesis is implicated in the development of atherosclerotic lesions. Thus, inhibition of angiogenesis may provide a novel therapeutic approach for the treatment of atherosclerosis. Because epidemiological studies have indicated an inverse relation between red wine intake and coronary disease, we determined the antiangiogenic potential of red wine polyphenols (RWPs) in the ischemic hindlimb model. Neovascularization was accelerated by the chronic infusion of angiotensin II (Ang II; 0.1 mg/kg/day). RWPs (25 mg/kg/day) or vehicle were administrated in the drinking water 7 days before the ligation. After 21 days, Ang II potentiated the ischemia-induced neovascularization in the hindlimb, as assessed by microangiography and measurement of microvessel density. This effect was associated with an increased formation of reactive oxygen species (ROS) and increased expression of hypoxia-inducible factor (HIF)-2alpha, endothelial nitric-oxide synthase (eNOS), and vascular endothelial growth factor (VEGF). RWPs intake significantly prevented the angiogenic process, the formation of ROS and nitrated proteins, and the expression HIF-2alpha, eNOS, and VEGF induced by Ang II. Similar preventive effects were observed with the antioxidant and NADPH oxidase inhibitor apocynin. These findings indicate that RWPs have potent antiangiogenic properties in vivo by preventing the expression of proangiogenic factors, including VEGF and eNOS most likely by inhibiting oxidative stress. Thus, the antiangiogenic properties of red wine polyphenols might contribute to their protective effect against coronary disease.
对动物和人类的研究均表明,血管生成与动脉粥样硬化病变的发展有关。因此,抑制血管生成可能为动脉粥样硬化的治疗提供一种新的治疗方法。由于流行病学研究表明红酒摄入量与冠心病之间呈负相关,我们在缺血后肢模型中测定了红酒多酚(RWP)的抗血管生成潜力。通过慢性输注血管紧张素II(Ang II;0.1mg/kg/天)可加速新血管形成。在结扎前7天,将RWP(25mg/kg/天)或赋形剂加入饮用水中。21天后,通过微血管造影和微血管密度测量评估,Ang II增强了后肢缺血诱导的新血管形成。这种效应与活性氧(ROS)形成增加以及缺氧诱导因子(HIF)-2α、内皮型一氧化氮合酶(eNOS)和血管内皮生长因子(VEGF)表达增加有关。摄入RWP可显著阻止Ang II诱导的血管生成过程、ROS和硝化蛋白的形成以及HIF-2α、eNOS和VEGF的表达。抗氧化剂和NADPH氧化酶抑制剂夹竹桃麻素也观察到类似的预防作用。这些发现表明,RWP在体内具有强大的抗血管生成特性,可能是通过抑制氧化应激来阻止包括VEGF和eNOS在内的促血管生成因子的表达。因此,红酒多酚的抗血管生成特性可能有助于其对冠心病的保护作用。